Add like
Add dislike
Add to saved papers

Automated CT volumetry of pulmonary metastases: the effect of a reduced growth threshold and target lesion number on the reliability of therapy response assessment using RECIST criteria.

European Radiology 2007 October
The purpose of this study was to evaluate the reproducibility of CT-volumetric tumour response assessment of pulmonary metastasis using variable volume change thresholds (VCT) and target lesions with response evaluation criteria in solid tumours (RECIST). Fifty consecutive patients with pulmonary metastases undergoing follow-up multislice CT under chemotherapy were assessed for response to chemotherapy with modifications to RECIST: (1) decreasing the percentual VCT for diagnosis of tumour response (range = 70%-20%), (2) reducing the number of target lesions (range = 1-5). Continuous and categorical observer agreements were tested by Bland and Altman and extended (kappa(e)) or non-weighted kappa (kappa) and correlated with percentual VCT to predict observer agreement. A total of 202 metastases were evaluated (average volume = 522.4 mm(3) +/- 902.4 mm(3)). General agreement on treatment response was very high (kappa(e) = 0.93-1), but was reduced with VCT < 35% (kappa(e) < 0.95). Kappa correlation with VCT values was strong (r=0.94-0.96; p< or =0.0002). Average confidence decreased significantly at VCT < 45% (p < 0.01) and agreement on stable disease at VCT < 35% (kappa(e) < 0.95; p < 0.01). Reduction of target lesions (n < 3; VCT = 35%) resulted in decreased reader confidence (for n = 1: kappa = 0.49; p < 0.05). Agreement for evaluation of treatment response was robust using VCT > or =35% and > or =3 metastases. This may translate into shortening of follow-up intervals or enable for response assessment with tumours displaying minimal volume change.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app